Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3084555 | 0.89 | KMT2A (0.53) | TRPV1ALOX15 | |
| SCHEMBL3092254 | 0.89 | KMT2A (0.53) | TRPV1ALOX15 | |
| SCHEMBL3084553 | 0.89 | KMT2A (0.53) | TRPV1ALOX15 | |
| SCHEMBL3092262 | 0.89 | KMT2A (0.53) | TRPV1ALOX15 | |
| SCHEMBL9633727 | 0.83 | NOS3 (0.39) | TRPV1ALOX15 | |
| SCHEMBL107820 | 0.83 | ESR1 (0.54) | TAAR1TDP1L3MBTL1 | |
| SCHEMBL10988255 | 0.82 | TRPA1 (0.46) | CYP1A2CYP2A6TAAR1IGF1RALOX15 | |
| SCHEMBL9633317 | 0.81 | ALDH1A1 (0.36) | TRPV1 | |
| SCHEMBL4769318 | 0.81 | TAAR1 (0.45) | TAAR1TRPV1GPR52 | |
| SCHEMBL105976 | 0.80 | TRPV1 (0.51) | TRPV1ALOX15GPR52TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629268-B2 | Cyclisation process of forming a multiple ring compound | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2014-01-14 | — | — | US | disclosed |
| US-20130046090-A1 | CYCLISATION PROCESS OF FORMING A MULTIPLE RING COMPOUND | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2013-02-21 | — | — | US | disclosed |
| US-8227645-B2 | Cyclisation process of forming a multiple ring compound | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2012-07-24 | — | — | US | disclosed |
| US-20100228058-A1 | CYCLISATION PROCESS OF FORMING A MULTIPLE RING COMPOUND | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2010-09-09 | — | — | US | disclosed |
| WO-2007097719-A1 | CYCLISATION PROCESS OF FORMING A MULTIPLE RING COMPOUND | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100228058-A1 | CYCLISATION PROCESS OF FORMING A MULTIPLE RING COMPOUND | DHPS, GGPS1, COASY | CYP1A2 147/4885CYP2A6 89/4885TAAR1 4216/4885 |
| US-20130046090-A1 | CYCLISATION PROCESS OF FORMING A MULTIPLE RING COMPOUND | COASY, AKR1C4, AKR1C2 | CYP1A2 114/4885CYP2A6 51/4885TAAR1 3463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.